Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15C30% of individuals with BRAFV600E metastatic melanoma treated with BRAF inhibitors (BRAFi). cuSCC cells, vemurafenib (a medically approved BRAFi) elevated ERK phosphorylation and gentle agar colony development; both responses had been greatly reduced by celecoxib. In medical tests trametinib, a MEK inhibitor (MEKi) raises BRAFi… Continue reading Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15C30%